• Home
  • About Us
    • About Us
    • Subscribe
    • Privacy Policy
  • Advertise
    • Advertise On IP Watch
    • Editorial Calendar
  • Videos
  • Links
  • Help

Intellectual Property Watch

Original news and analysis on international IP policy

  • Copyright
  • Patents
  • Trademarks
  • Opinions
  • People News
  • Venues
    • Bilateral/Regional Negotiations
    • ITU/ICANN
    • United Nations – other
    • WHO
    • WIPO
    • WTO/TRIPS
    • Africa
    • Asia/Pacific
    • Europe
    • Latin America/Caribbean
    • North America
  • Themes
    • Access to Knowledge/ Open Innovation & Science
    • Food Security/ Agriculture/ Genetic Resources
    • Finance
    • Health & IP
    • Human Rights
    • Internet Governance/ Digital Economy/ Cyberspace
    • Lobbying
    • Technical Cooperation/ Technology Transfer
  • Health Policy Watch

New UNCTAD, GIZ Toolbox: How To Achieve Policy Coherence For Local Production And Access To Medicines

05/12/2017 by Guest contributor for Intellectual Property Watch Leave a Comment

Share this:

  • Click to share on Twitter (Opens in new window)
  • Click to share on LinkedIn (Opens in new window)
  • Click to share on Facebook (Opens in new window)
  • Click to email this to a friend (Opens in new window)
  • Click to print (Opens in new window)

What do investment, trade, intellectual property, health financing, R&D, industrial and medicines regulation policy have in common? They are all important building blocks for the successful promotion of local pharmaceutical manufacturing. As more and more countries are looking into building their own pharmaceutical production capacities, they need to ensure strong policy coherence to be successful.

Tool Box for Policy Coherence in Access to Medicines and Local Pharmaceutical Production

Done rightly, local pharmaceutical manufacturing can be an important part of a country’s health system by shortening supply chains, building emergency capacity and aligning production specifics more with the domestic population. Bangladesh’s success of producing 80% of the country’s demand for medicines or Brazil’s experience in issuing compulsory licenses to locally produce patent-protected and expensive medicines during an HIV epidemic are illustrative examples of how a local industry can serve public health goals. Yet, if public health policies are not in sync with industrial policies, access to medicines may not improve. A case in point is India: having built up one of the largest generic pharmaceutical industries worldwide, yet showing low access to medicines domestically.

So, how do policy makers ensure that local pharmaceutical production is supported without undermining the public health need for affordable (imported) medicines? And how do states match their ambition with their commitments to the rules of international trade? The “Tool Box for Policy Coherence in Access to Medicines and Local Pharmaceutical Production” gives answers for policy makers and development professionals.

In line with its title, the document offers hands-on policy advice, with many case studies and a tableau of solutions to specific problems. It is a joint publication by the GIZ Global Project “Access to Medicines” and the United Nations Conference on Trade and Development (UNCTAD).

The publication is available following this link:  http://unctad.org/en/pages/PublicationWebflyer.aspx?publicationid=1921

 

Image Credits: GIZ, UNCTAD

Share this:

  • Click to share on Twitter (Opens in new window)
  • Click to share on LinkedIn (Opens in new window)
  • Click to share on Facebook (Opens in new window)
  • Click to email this to a friend (Opens in new window)
  • Click to print (Opens in new window)

Related

Guest contributor may be reached at info@ip-watch.ch.

Creative Commons License"New UNCTAD, GIZ Toolbox: How To Achieve Policy Coherence For Local Production And Access To Medicines" by Intellectual Property Watch is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License.

Filed Under: IP Policies, Language, Themes, Venues, Development, English, Europe, Health & IP, Health Policy Watch, Innovation/ R&D, Patents/Designs/Trade Secrets, Regional Policy, Technical Cooperation/ Technology Transfer, United Nations - other, WHO

Leave a Reply Cancel reply

Your email address will not be published. Required fields are marked *

This site uses Akismet to reduce spam. Learn how your comment data is processed.

  • Email
  • Facebook
  • LinkedIn
  • RSS
  • Twitter
  • Vimeo
My Tweets

Perspectives on the US

In US, No Remedies For Growing IP Infringements

US IP Law – Big Developments On The Horizon In 2019

More perspectives on the US...

Supported Series: Civil Society And TRIPS Flexibilities

Civil Society And TRIPS Flexibilities Series – Translations Now Available

The Myth Of IP Incentives For All Nations – Q&A With Carlos Correa

Read the TRIPS flexibilities series...

Top Global Health stories

New WHO Director Tedros’s Opening Vision: People First

Enter The African Medicines Agency, Continent’s First Super-Regulator?

More health stories...

Paid Content

Interview With Peter Vanderheyden, CEO Of Article One Partners

More paid content...

IP Delegates in Geneva

  • IP Delegates in Geneva
  • Guide to Geneva-based Public Health and IP Organisations

All Story Categories

Other Languages

  • Français
  • Español
  • 中文
  • اللغة العربية

Archives

  • Archives
  • Monthly Reporter

Staff Access

  • Writers

Sign up for free news alerts

This site uses cookies to help give you the best experience on our website. Cookies enable us to collect information that helps us personalise your experience and improve the functionality and performance of our site. By continuing to read our website, we assume you agree to this, otherwise you can adjust your browser settings. Please read our cookie and Privacy Policy. Our Cookies and Privacy Policy

Copyright © 2025 · Global Policy Reporting

loading Cancel
Post was not sent - check your email addresses!
Email check failed, please try again
Sorry, your blog cannot share posts by email.